Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 6 | 0 | 6 |
| 2000 | 3 | 1 | 4 |
| 2001 | 3 | 4 | 7 |
| 2002 | 3 | 14 | 17 |
| 2003 | 6 | 10 | 16 |
| 2004 | 2 | 15 | 17 |
| 2005 | 8 | 7 | 15 |
| 2006 | 7 | 4 | 11 |
| 2007 | 12 | 15 | 27 |
| 2008 | 11 | 4 | 15 |
| 2009 | 9 | 5 | 14 |
| 2010 | 16 | 10 | 26 |
| 2011 | 9 | 5 | 14 |
| 2012 | 11 | 11 | 22 |
| 2013 | 13 | 8 | 21 |
| 2014 | 8 | 6 | 14 |
| 2015 | 6 | 11 | 17 |
| 2016 | 7 | 5 | 12 |
| 2017 | 8 | 7 | 15 |
| 2018 | 6 | 6 | 12 |
| 2019 | 9 | 7 | 16 |
| 2020 | 6 | 8 | 14 |
| 2021 | 4 | 6 | 10 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 5 | 6 |
| 2024 | 1 | 4 | 5 |
| 2025 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Folliculin Deletion in the Mouse Kidney Results in Cystogenesis of the Loops of Henle via Aberrant TFEB Activation. Am J Pathol. 2025 Sep; 195(9):1643-1659.
-
Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation. Cell Death Differ. 2025 Aug; 32(8):1460-1472.
-
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun. 2025 Mar 17; 16(1):2632.
-
MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas. Clin Epigenetics. 2025 Feb 20; 17(1):28.
-
DNA-binding affinity and specificity determine the phenotypic diversity in BCL11B-related disorders. Am J Hum Genet. 2025 Feb 06; 112(2):394-413.
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1637-1644.
-
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer. 2024 Nov 05; 12(11).
-
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
-
Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimers Dement. 2024 Dec; 20(12):8470-8483.
-
Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables. Lab Invest. 2024 12; 104(12):102160.